Oncolytics Biotech (ONCY) Total Non-Current Liabilities (2009 - 2022)
Oncolytics Biotech (ONCY) posted quarterly Total Non-Current Liabilities of $8.0 million for Q4 2022, up 63.21% year-over-year from $4.9 million in Q4 2021, and up 73.87% quarter-over-quarter from $4.6 million in Q1 2022.
Oncolytics Biotech (ONCY) Total Non-Current Liabilities (2009 - 2022) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Total Non-Current Liabilities for 11 consecutive years, with $8.0 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Total Non-Current Liabilities rose 63.21% year-over-year to $8.0 million; the TTM figure through Dec 2022 stood at $8.0 million (up 63.21% YoY), while the FY2022 annual figure was $8.3 million, up 69.42% from the prior year.
- Total Non-Current Liabilities climbed to $8.0 million in Q4 2022 per ONCY's latest filing, from $4.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $8.8 million in Q3 2019 and bottomed at $4.4 million in Q4 2018.
- Historically, Total Non-Current Liabilities has averaged $6.1 million across 5 years, with a median of $5.8 million in 2018.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 100.0% in 2018 and fell as far as 100.0% in 2018.
- Oncolytics Biotech's Total Non-Current Liabilities stood at $4.4 million in 2018, then grew by 17.77% to $5.2 million in 2019, then increased by 1.07% to $5.3 million in 2020, then fell by 7.4% to $4.9 million in 2021, then soared by 63.21% to $8.0 million in 2022.
- Business Quant data shows ONCY's Total Non-Current Liabilities at $8.0 million in Q4 2022, $4.6 million in Q1 2022, and $4.9 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 9.32 Bn |
| 10 | Oncolytics Biotech | 98.95 Mn | 98.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 7.98 Mn |
| Mar 31, 2022 | 4.59 Mn |
| Dec 31, 2021 | 4.89 Mn |
| Sep 30, 2021 | 5.70 Mn |
| Jun 30, 2021 | 5.89 Mn |
| Mar 31, 2021 | 5.61 Mn |
| Dec 31, 2020 | 5.28 Mn |
| Sep 30, 2020 | 6.91 Mn |
| Jun 30, 2020 | 6.75 Mn |
| Mar 31, 2020 | 6.82 Mn |
| Dec 31, 2019 | 5.22 Mn |
| Sep 30, 2019 | 8.75 Mn |
| Jun 30, 2019 | 7.05 Mn |
| Mar 31, 2019 | 6.22 Mn |
| Dec 31, 2018 | 4.44 Mn |
| Sep 30, 2018 | 5.86 Mn |
| Jun 30, 2018 | 5.80 Mn |
| Mar 31, 2018 | 5.26 Mn |
| Dec 31, 2017 | 3.65 Mn |
| Sep 30, 2017 | -3,617.90 Bn |